Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 296

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

Open access
Stanczak, Michal A., Siddiqui, Shoib S., Trefny, Marcel P., Thommen, Daniela S., Boligan, Kayluz Frias, von Gunten, Stephan, Tzankov, Alexandar, Tietze, Lothar, Lardinois, Didier, Heinzelmann-Schwarz, Viola, von Bergwelt-Baildon, Michael, Zhang, Wu, Lenz, Heinz-Josef, Han, Younghun, Amos, Christopher I., Syedbasha, Mohammedyaseen, Egli, Adrian, Stenner, Frank, Speiser, Daniel E., Varki, Ajit, Zippelius, Alfred, Läubli, Heinz·2018·Journal of Clinical Investigation

Abstract

First-generation immune checkpoint inhibitors, including anti-CTLA-4 and anti-programmed death 1 (anti-PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid-binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9-expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anticancer immunity. T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. Our data identify the sialoglycan-SAMP/Siglec pathway as a potential target for improving T cell activation for immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci120612

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 296

Metadata

Authors
Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., von Bergwelt-Baildon, M., Zhang, W., Lenz, H.-J., Han, Y., Amos, C. I., Syedbasha, M., Egli, A., Stenner, F., Speiser, D. E., Varki, A., Zippelius, A., & Läubli, H.
Venue
Journal of Clinical Investigation
Published
2018-09-24
Volume
128
Issue
11
Pages
4912-4923
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2888330968
Cited by
296
References
9
FWCI
8.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. https://app.cochat.ai/papers/10.1172/jci120612
The paper
Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., von Bergwelt-Baildon, M., Zhang, W., Lenz, H.-J., Han, Y., Amos, C. I., Syedbasha, M., Egli, A., Stenner, F., Speiser, D. E., . . . Läubli, H. (2018). Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci120612

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.